IGlar U100 offered asignificant development in basal insulin therapy by demonstrating a solution formulation withreduced nocturnal hypoglycemia compared to NPH due to its flatter metabolic activity profileand by introducing the concept of a simple treat-to-target dosing regimen for weekly titrationbased on daily fasting glucose levels that changed the standards of care for insulinmanagement in type 2 diabetes (T2D) (3-5). The gene discussed is INS; the disease is type 2 diabetes mellitus.